Arrowhead Pharmaceuticals reported a GAAP loss of $47.55 million for the six months of fiscal year 2021, up 2.1 times from $22.509 million in the prior year. Revenue increased 2.1% to $54.113 million compared to $52.983 million a year earlier.
Arrowhead Pharmaceuticals reported a GAAP loss of $47.55 million for the six months of fiscal year 2021, up 2.1 times from $22.509 million in the prior year. Revenue increased 2.1% to $54.113 million compared to $52.983 million a year earlier. 
ir.arrowheadpharma.com
English (US) 